The Latest Breaking News from LXRX

At the American College of Cardiology, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) highlighted a new data analysis from the SCORED Phase 3 trial of sotagliflozin in Type 2 diabetes and kidney disease patients. Sotagliflozin significantly reduced major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke compared to placebo. Also See: Lexicon Announces…

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) entered into a loan facility with Oxford Finance LLC for $150 million to support commercial preparations and the potential launch of sotagliflozin in heart failure. The loan facility consists of four tranches, each maturing in March 2027. An initial $25 million tranche was funded at closing. The second $25 million tranche…